MarketBeat
06 Jun 2026, 04:02 UTC · 3h ago
Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline
MarketBeat
06 Jun 2026, 04:02 UTC · 3h ago
Story key points
6 claims · impact-rated
Axsome is launching Auvelity for Alzheimer’s disease agitation this month, targeting a market with over 20 million annual prescriptions (95% currently off-label). — Expanding a high-revenue drug into a massive, underserved indication with significant off-label use represents a major growth catalyst.
+0.80The company has doubled its Auvelity sales force from 300 to approximately 630 representatives to drive top-line growth. — Aggressive commercial scaling typically precedes revenue acceleration, though it increases operational spend.
+0.50Auvelity's peak sales guidance has been raised to $8 billion. — Upward revisions of peak sales targets signal management's high confidence in market penetration and long-term value.
+0.40Continue reading
6 related stories
Search tags
Auvelity's current run rate in major depressive disorder is approximately $600 million with 86% covered lives. — Strong baseline performance and high payer coverage validate the product's market viability ahead of new indications.
+0.30Axsome is advancing four additional Phase 3 indications for Sunosi, including ADHD, binge eating disorder, and shift work disorder. — Diversification of the pipeline reduces single-product risk, though these are longer-term catalysts.
+0.20The company expects potential Medicare drug price negotiations under the Inflation Reduction Act to affect Auvelity in 2031 or 2032. — While a negative headwind, the long time horizon (7+ years) minimizes the immediate impact on valuation.
-0.10Ticker attribution
Model heads
The company is launching Auvelity for a new indication, reporting strong current run rates, expanding its sales force, and advancing multiple Phase 3 pipeline candidates.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Newsfile Corp
3h ago
